Sumitomo Pharma will execute a bridge loan refinancing of existing borrowings consisting of a term loan of 20 billion yen and a commitment line of 130 billion yen for the period from April 24, 2026 to April 23, 2027.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-04-08","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/04\/4506-20260408-02.pdf","jir_short_summary":"Sumitomo Pharma will execute a bridge loan refinancing of existing borrowings consisting of a term loan of 20 billion yen and a commitment line of 130 billion yen for the period from April 24, 2026 to April 23, 2027.","jir_summary":"### Overview of Refinancing\nSumitomo Pharma Co., Ltd. has decided, as of April 8, 2026, to refinance existing borrowings with a bridge loan for the purpose of wholly acquiring Myovant Sciences and forming a strategic partnership with Roivant Sciences. Concurrently with a new share issuance and secondary offering, existing borrowings guaranteed by Sumitomo Chemical Co., Ltd. will be fully repaid and replaced with the bridge loan without such guarantee. The borrowing amounts are 20 billion yen as a term loan and 130 billion yen as a commitment line, with the term from April 24, 2026 to April 23, 2027, and repayment in a lump-sum at maturity.\n\n### Details of Existing Borrowings and Future Outlook\nThe existing syndicated loan subject to repayment includes an outstanding balance of 60 billion yen out of 140 billion yen of term loan (Tranche A), and 38.1 billion yen out of 93 billion yen of commitment line (Tranche B). The existing loans were guaranteed by Sumitomo Chemical Co., Ltd. for the period from March 31, 2025 to March 31, 2028. Through this refinancing, the loans will be switched to a bridge loan without guarantees. The impact of this matter on consolidated results for the fiscal year ending March 2027 is expected to be minor.","jir_financial_highlights":"Bridge loan contract amount (Term Loan): 20 billion yen (Unknown)\nBridge loan contract amount (Commitment Line): 130 billion yen (Unknown)\nOutstanding principal balance of existing syndicated loans (as of April 8, 2026): Term Loan 60 billion yen, Commitment Line 38.1 billion yen (Unknown)","jir_category":"","jir_hashtags":"#SumitomoPharma, #generalIR, #BorrowingRefinancing","jir_key_figures":"Term Loan Contract Amount: 20 billion yen\nCommitment Line Contract Amount: 130 billion yen\nOutstanding Principal Balance of Existing Syndicated Loans: Term Loan 60 billion yen, Commitment Line 38.1 billion yen","jir_meta_title":"Sumitomo Pharma Decides on Refinancing Borrowings with 20 Billion Yen Term Loan and 130 Billion Yen Commitment Line","jir_meta_description":"Sumitomo Pharma Co., Ltd. announced on April 8, 2026, that it will execute a bridge loan refinancing of existing borrowings totaling 20 billion yen in term loans and 130 billion yen in commitment lines. The impact on earnings for the fiscal year ending March 2027 is expected to be minor.","jir_og_title":"Sumitomo Pharma Announces Refinancing of Existing Borrowings","jir_og_description":"On April 8, 2026, Sumitomo Pharma refinanced existing borrowings through a bridge loan totaling approximately 150 billion yen, with minimal impact on financial results.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"general_ir","footnotes":""},"sector":[],"importance":[],"class_list":["post-39522","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n